Clinical Trial Update: Efficacy and Safety of 1% Atropine "5+3" Regimen in Children and Adolescents Controlling Myopia [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating efficacy and safety of a 1% atropine '5+3' regimen for myopia control in children and adolescents.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopia

Drugs mentioned

• 1% atropine '5+3' regimen (atropine 1%)

Snippet

Sponsor: Shanghai Eye Disease Prevention and Treatment Center | Conditions: Myopia | Phase 4 | Status: UNKNOWN